Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
| ▸ | FABP4 | P15090 | 2/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.31 |
| ▸ | CDK4 | P11802 | 1/20 | 0.31 |
| ▸ | CCND1 | P24385 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24109740 | 1.00 | HTR2A (0.37) | HTR2AHTR2CMAPTRXFP1TFPI2 | |
| SCHEMBL24109741 | 0.88 | HTR2A (0.37) | HTR2AHTR2CFABP4CYP1A2CYP2A6 | |
| SCHEMBL25817984 | 0.87 | TFPI2 (0.36) | HTR2AHTR2CMAPTRXFP1TFPI2 | |
| SCHEMBL25819158 | 0.87 | TFPI2 (0.36) | HTR2AHTR2CMAPTRXFP1TFPI2 | |
| SCHEMBL24110272 | 0.87 | TFPI2 (0.36) | HTR2AHTR2CMAPTRXFP1TFPI2 | |
| SCHEMBL24109704 | 0.84 | HTR2A (0.38) | HTR2AHTR2CTFPI2FABP4MAOB | |
| SCHEMBL25820588 | 0.83 | SCN9A (0.32) | — | |
| SCHEMBL24110197 | 0.83 | SCN9A (0.32) | — | |
| SCHEMBL24109711 | 0.81 | HTR2C (0.42) | HTR2AHTR2CTFPI2ROCK1FABP4 | |
| SCHEMBL25820772 | 0.81 | HTR2C (0.42) | HTR2AHTR2CTFPI2ROCK1FABP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219969-A1 | ISOTRYPTAMINE PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219969-A1 | ISOTRYPTAMINE PSYCHOPLASTOGENS AND USES THEREOF | GAP43, SLC18A2, PNMT | HTR2A 10/4885HTR2C 35/4885MAPT 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.